Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Journey Medical (DERM) Gross Margin: 2020-2025

Historic Gross Margin for Journey Medical (DERM) over the last 5 years, with Sep 2025 value amounting to 67.36%.

  • Journey Medical's Gross Margin fell 208.00% to 67.36% in Q3 2025 from the same period last year, while for Sep 2025 it was 66.05%, marking a year-over-year decrease of 201.00%. This contributed to the annual value of 62.81% for FY2024, which is 828.00% down from last year.
  • Per Journey Medical's latest filing, its Gross Margin stood at 67.36% for Q3 2025, which was up 0.40% from 67.09% recorded in Q2 2025.
  • In the past 5 years, Journey Medical's Gross Margin ranged from a high of 85.27% in Q4 2023 and a low of 43.05% during Q3 2021.
  • Moreover, its 3-year median value for Gross Margin was 65.64% (2024), whereas its average is 65.19%.
  • Per our database at Business Quant, Journey Medical's Gross Margin plummeted by 2,318bps in 2021 and then surged by 3,361bps in 2023.
  • Journey Medical's Gross Margin (Quarterly) stood at 45.62% in 2021, then soared by 604bps to 51.66% in 2022, then surged by 3,361bps to 85.27% in 2023, then plummeted by 1,963bps to 65.64% in 2024, then slumped by 208bps to 67.36% in 2025.
  • Its Gross Margin stands at 67.36% for Q3 2025, versus 67.09% for Q2 2025 and 63.54% for Q1 2025.